{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-22-000050","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.746143+00:00","generated_at":"2026-06-24T02:53:53.742712+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Krystal Biotech Q2 net loss widens to $28.1M; BLA filed for B-VEC, KB407 IND accepted","bullets":["Q2 net loss $28.1M ($1.10/share) vs $16.4M loss YoY; cash $438.5M.","Filed BLA for B-VEC (DEB therapy) with FDA on June 22, 2022.","FDA accepted IND for KB407 (cystic fibrosis); Phase 1 trials expected 2H 2022.","R&D expense $10.9M, G&A $17.9M; losses reflect increased commercial prep.","Pipeline: KB105 dosing to resume 2H 2022; KB104 IND later 2022; KB301 Phase 2 in Q4 2022/Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-22-000050","json":"https://secwatch.observer/filing/0001711279-22-000050.json","markdown":"https://secwatch.observer/filing/0001711279-22-000050.md","text":"https://secwatch.observer/filing/0001711279-22-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127922000050/0001711279-22-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127922000050/krys-20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:53:53.742712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}